Can Pembrolizumab (MK3475) with SBRT Treatment Stop or Slow Non-Small Cell Lung Cancer?

Trial Objective

Can Pembrolizumab (MK3475) with SBRT Treatment Stop or Slow Non-Small Cell Lung Cancer?  (KEYNOTE-867 Study)The purpose of this study is to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) plus pembrolizumab (MK-3475) in the treatment of adult participants with medically inoperable Stage I or IIA non-small cell lung cancer (NSCLC).


New enrollment for this trial is temporarily paused

Who Can Participate

You may be able to join this study if you are at least 18 years old, with medically inoperable Stage I/IIA NSCLC and if you have not received prior anticancer therapy for lung cancer.

Age: 18+    Gender: Any Gender

Estimated Time Commitment

Up to 7 years

If you are eligible and choose to be in the study, your participation will last up to 7 years. You will be asked to visit the study site about 26 times.

Payment & Reimbursement  

Payment: Not Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Jami Henriksen

Jami Henriksen

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Merck Sharp & Dohme Corp.

Principal Investigators


Request More Information

Due to concerns around COVID-19 and our focus on helping to meet this momentous challenge, we have temporarily paused enrollment for all trials requiring an in-person visit. Please feel free to request additional information about any of the trials we have posted and we will get back to you when enrollment resumes. For more resources and information on COVID-19 please visit our special coronavirus website at